N/A
N=4
Health Coaching for Glaucoma Patients
Glaucoma
Bottom Line
View on ClinicalTrials.gov: NCT02090777 ↗Enrolled (actual)
4
Serious AEs
0.0%
Results posted
Mar 2016
Primary outcome: Primary: Glaucoma Medication Adherence — 72 percentage of adherence time
Study Design & Population
- Study type
- Interventional
- Phase
- N/A
- Interventions
- Health Coach (Behavioral)
- Age
- Adult, Older Adult · 18+ yrs
- Sex
- All
- Sponsor
- Duke University
- Primary completion
- Apr 2015
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Glaucoma Medication Adherence |
72 | — |
Summary
The study will be conducted to examine the feasibility of using a Health Coach for improving the ophthalmic care of glaucoma patients. Patients taking glaucoma medications will have a coaching intervention and adherence to glaucoma drops will be monitored using a dose-recording device. The dosing data will be analyzed to examine the effect on adherence and qualitative interviews at the conclusion of the study will be used to examine which elements of the coaching experience were most helpful in the glaucoma patient population.
Eligibility Criteria
Inclusion Criteria
- Adult whose age is >18 years
- Diagnosed with glaucoma
- Patient of Duke Glaucoma Service
- Prescribed or using topical glaucoma eye medication for at least 6 months
- Primarily self-administering his or her eye drops
- English speaking
- Patient should be able to use the telephone for the coaching intervention,
- Patient should be available by phone to complete the coaching intervention
- Patient should be willing and able to use the MEMS (Medication Event Monitoring System) device for recording medication use
- Patient must be willing and able to come to the Eye Center for an exit interview and to return the MEMS device
- Patient must be able to give consent
Exclusion Criteria
- Patient should be excluded if he or she may need glaucoma surgery or laser during the 6 months of the study period
Data sourced from ClinicalTrials.gov (NCT02090777). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.